Aurinia Pharmaceuticals
AUPH
69 hedge funds and large institutions have $109M invested in Aurinia Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 13 closing their positions.
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
11% more funds holding
Funds holding: 62 → 69 (+7)
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
0.47% more ownership
Funds ownership: 28.06% → 28.53% (+0.47%)
26% less capital invested
Capital invested by funds: $147M → $109M (-$38.4M)
71% less call options, than puts
Call options by funds: $865K | Put options by funds: $2.99M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
+$3.78M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.98M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$2.3M |
| 5 |
Goldman Sachs
New York
|
+$1.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.74M |
| 2 |
CLCM
Crawford Lake Capital Management
Lakewood,
New Jersey
|
-$2.86M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$2.08M |
| 4 |
Morgan Stanley
New York
|
-$1.13M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$929K |
AUPH Hedge Fund Activity: Q4 2017 in Review
69 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2017, worth a combined $109M — down 26% from $147M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new AUPH positions and 13 closed out — a net gain of 7 holders — while 17 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $4M. The largest seller was Fidelity Investments, cutting an estimated $5.74M.
- 69 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2017, up from 62 in Q3 2017.
- Funds reported $109M of Aurinia Pharmaceuticals stock for Q4 2017, down 26% quarter-over-quarter.
- 20 funds opened new Aurinia Pharmaceuticals positions in Q4 2017 and 13 closed out, a net change of +7 holders.
- The largest Aurinia Pharmaceuticals buyer in Q4 2017 was BlackRock, an estimated $4M added.
- The largest Aurinia Pharmaceuticals seller in Q4 2017 was Fidelity Investments, an estimated $5.74M sold.
Based on aggregated 13F filings for Q4 2017.